What evidence supports the use of adjuvant abiraterone (abiraterone acetate) after definitive radical radiotherapy in patients with high‑risk locally advanced prostate cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Adjuvant Abiraterone After Radical Radiotherapy for High-Risk Locally Advanced Prostate Cancer

Men with very high-risk M0 prostate cancer (defined as N1 disease or at least two risk factors among T3-T4, PSA >40 ng/mL, Gleason score 8-10) receiving radical radiotherapy should receive 24 months of abiraterone plus prednisone combined with 24-36 months of ADT. 1

Evidence Strength and Recommendation Grade

The 2023 ESMO guidelines provide a Level I, Grade B recommendation for this combination based on the updated STAMPEDE trial analysis 1. This represents the highest quality guideline evidence available, though notably neither the EMA nor FDA have approved abiraterone for use in M0 disease 1.

Key Supporting Data from STAMPEDE

The updated STAMPEDE phase III trial demonstrated compelling benefits in the very high-risk M0 population:

  • Metastasis-free survival: HR 0.54 (95% CI 0.43-0.68, P = 3.2×10⁻¹⁰) 1
  • Overall survival: HR 0.63 (95% CI 0.48-0.82, P = 0.0005) 1

A comprehensive meta-analysis of STAMPEDE data in 1,974 patients with high-risk non-metastatic disease showed 2:

  • Metastasis-free survival: HR 0.53 (95% CI 0.44-0.64, p<0.0001)
  • Overall survival: HR 0.60 (95% CI 0.48-0.73, p<0.0001)
  • 6-year metastasis-free survival: 82% vs 69% (combination vs control)
  • Prostate cancer-specific survival: HR 0.49 (95% CI 0.37-0.65, p<0.0001)

Treatment Protocol

Specific regimen 1:

  • Abiraterone acetate 1000 mg daily (or 500 mg of fine-particle formulation)
  • Prednisone 5 mg twice daily
  • Duration: 24 months
  • Combined with long-course ADT: 24-36 months
  • Radiotherapy as per local guidelines (typically 74 Gy in 37 fractions or equivalent)

Safety Profile

Grade 3+ adverse events occurred in 37% of patients receiving abiraterone plus ADT versus 29% with ADT alone in the STAMPEDE abiraterone-only arm 2. The most common grade 3+ events were:

  • Hypertension: 5% (vs 1% control) 2
  • Elevated transaminases: 6% (vs <1% control) 2
  • Lymphopenia: 14% in smaller phase II studies 3

Critical monitoring requirements:

  • Blood pressure monitoring for hypertension
  • Liver function tests for transaminitis
  • Electrolytes for hypokalemia (17% incidence) 4
  • Cardiac monitoring (atrial fibrillation in 4%) 4

Important Caveats

Off-label use: This indication remains off-label as FDA approval is limited to metastatic castration-resistant prostate cancer 5. The FDA label specifically states abiraterone is indicated "for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC)" 5, not for M0 disease.

Patient selection: The benefit is specifically established for very high-risk M0 disease. The definition requires either:

  • N1 (node-positive) disease, OR
  • At least 2 of: T3-T4, PSA >40 ng/mL, Gleason 8-10 1

Radiotherapy requirement: The STAMPEDE data mandated radiotherapy for node-negative patients and encouraged it for node-positive disease, with 85% receiving planned radiotherapy 2. This combination should not be extrapolated to patients not receiving definitive radiotherapy.

Practical Implementation

The NCCN 2025 guidelines 4 discuss abiraterone extensively for metastatic CRPC but do not include specific recommendations for the M0 adjuvant setting post-radiotherapy, highlighting the regulatory gap despite strong trial evidence.

When enzalutamide was added to abiraterone in STAMPEDE, no additional benefit was observed (interaction HR 1.02,95% CI 0.70-1.50, p=0.91) 2, so dual ARPI therapy is not recommended.

Related Questions

In a patient with high‑risk locally‑advanced prostate cancer, when should radiotherapy be administered relative to the initiation of abiraterone (100 mg daily) with prednisone?
What is the evidence supporting the use of adjuvant abiraterone (with prednisone) in patients with high‑risk (cT3a N0 M0) acinar prostate adenocarcinoma after definitive radiotherapy?
What is the prognosis for a patient with a Gleason score of 9 and a diagnosis of prostate cancer (Prostate Specific Antigen) (PSA)?
What are the key findings of the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) non-metastatic trial for a patient with high-risk non-metastatic prostate cancer, specifically T3aN0M0 disease and a Gleason score of 4+3?
What is the significance of 55 Gy in 20 fractions (Gray (Gy) in fractions) radiation dose in the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trial for prostate cancer treatment?
Does albuterol increase blood lactate levels?
What is the evidence supporting the use of adjuvant abiraterone (with prednisone) in patients with high‑risk (cT3a N0 M0) acinar prostate adenocarcinoma after definitive radiotherapy?
How long does extended-release metoprolol (metoprolol succinate) take to become therapeutic for palpitations?
What is the appropriate management for a 19-year-old outpatient telehealth patient presenting with insomnia?
Should I use prednisone or an alternative medication for my condition?
Is it safe for a dialysis patient to take midodrine 30 mg every six hours?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.